282 related articles for article (PubMed ID: 16239383)
1. Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis.
Mukhtyar C; Luqmani R
Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv31-6. PubMed ID: 16239383
[TBL] [Abstract][Full Text] [Related]
2. Etanercept plus standard therapy for Wegener's granulomatosis.
Wegener's Granulomatosis Etanercept Trial (WGET) Research Group
N Engl J Med; 2005 Jan; 352(4):351-61. PubMed ID: 15673801
[TBL] [Abstract][Full Text] [Related]
3. A brief history of Wegener's granulomatosis: on limited, localized, and generalized forms of the disease: comment on the article by the Wegener's Granulomatosis Etanercept Trial Research Group.
Lamprecht P; Gross WL
Arthritis Rheum; 2004 Jan; 50(1):334-5; author reply 335-6. PubMed ID: 14730635
[No Abstract] [Full Text] [Related]
4. Infliximab efficiency in refractory Wegener's granulomatosis.
Rozin A
Rheumatology (Oxford); 2003 Sep; 42(9):1124-5; author reply 1125-6. PubMed ID: 12923277
[No Abstract] [Full Text] [Related]
5. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET).
Seo P; Min YI; Holbrook JT; Hoffman GS; Merkel PA; Spiera R; Davis JC; Ytterberg SR; St Clair EW; McCune WJ; Specks U; Allen NB; Luqmani RA; Stone JH;
Arthritis Rheum; 2005 Jul; 52(7):2168-78. PubMed ID: 15986348
[TBL] [Abstract][Full Text] [Related]
6. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
Gerloni V; Pontikaki I; Gattinara M; Fantini F
Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor-alpha blockade and the risk of vasculitis.
Guillevin L; Mouthon L
J Rheumatol; 2004 Oct; 31(10):1885-7. PubMed ID: 15468348
[No Abstract] [Full Text] [Related]
8. TNF-alpha bioactivity-inhibiting therapy in ANCA-associated vasculitis: clinical and experimental considerations.
Huugen D; Tervaert JW; Heeringa P
Clin J Am Soc Nephrol; 2006 Sep; 1(5):1100-7. PubMed ID: 17699331
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
[TBL] [Abstract][Full Text] [Related]
10. [Infliximab in the treatment of Wegener's granulomatosis: case report].
Svozílková P; Ríhová E; Brichová M; Diblík P; Kuthan P; Poch T
Cesk Slov Oftalmol; 2006 Jul; 62(4):280-6. PubMed ID: 16895062
[TBL] [Abstract][Full Text] [Related]
11. Wegener's granulomatosis.
Lamprecht P; Gross WL
Herz; 2004 Feb; 29(1):47-56. PubMed ID: 14968341
[TBL] [Abstract][Full Text] [Related]
12. Differentiating the efficacy of tumor necrosis factor inhibitors.
Haraoui B
J Rheumatol Suppl; 2005 Mar; 74():3-7. PubMed ID: 15742457
[TBL] [Abstract][Full Text] [Related]
13. Drug insight: anti-tumor necrosis factor therapies for the vasculitic diseases.
Langford CA
Nat Clin Pract Rheumatol; 2008 Jul; 4(7):364-70. PubMed ID: 18506159
[TBL] [Abstract][Full Text] [Related]
14. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial.
Stone JH; Holbrook JT; Marriott MA; Tibbs AK; Sejismundo LP; Min YI; Specks U; Merkel PA; Spiera R; Davis JC; St Clair EW; McCune WJ; Ytterberg SR; Allen NB; Hoffman GS;
Arthritis Rheum; 2006 May; 54(5):1608-18. PubMed ID: 16646004
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab.
Mitoma H; Horiuchi T; Tsukamoto H; Tamimoto Y; Kimoto Y; Uchino A; To K; Harashima S; Hatta N; Harada M
Arthritis Rheum; 2008 May; 58(5):1248-57. PubMed ID: 18438840
[TBL] [Abstract][Full Text] [Related]
16. The utility of tumour necrosis factor blockade in orphan diseases.
Keystone EC
Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii79-ii83. PubMed ID: 15479879
[TBL] [Abstract][Full Text] [Related]
17. [Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center].
de Oliveira SK; de Almeida RG; Fonseca AR; Rodrigues MC; Sztajnbok F; Diniz C
Acta Reumatol Port; 2007; 32(2):139-50. PubMed ID: 17572652
[TBL] [Abstract][Full Text] [Related]
18. Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial.
Stone JH;
Arthritis Rheum; 2003 Aug; 48(8):2299-309. PubMed ID: 12905485
[TBL] [Abstract][Full Text] [Related]
19. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
Tynjälä P; Vähäsalo P; Honkanen V; Lahdenne P
Ann Rheum Dis; 2009 Apr; 68(4):552-7. PubMed ID: 18467515
[TBL] [Abstract][Full Text] [Related]
20. Infliximab as rescue therapy in three cases of paediatric Wegener's granulomatosis.
Wilkinson NM; Erendzhinova E; Zeft A; Cabral DA
Rheumatology (Oxford); 2006 Aug; 45(8):1047-8. PubMed ID: 16735453
[No Abstract] [Full Text] [Related]
[Next] [New Search]
